MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

NOV 1 6 LUV9 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for 1449B/PTO.

INFORMATION DISCUSSION
STATEMENT BY APPLICANT

Date Submitted: November 16, 2006

(use as many sheets as necessary)

1 of 1

Sheet

	Complete if Known	
Application Number	10/681,418	
Filing Date	October 7, 2003	
First Named Inventor	H. Michael SHEPARD	
Group Art Unit	1623	
Examiner Name	Crane, Lawrence E.	
Attorney Docket Number	060925-0801	_

U.S. PATENT DOCUMENTS									
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			

			U.S	. PATENT APPLICATION DOCU	MENTS	
Examiner	Cite	U.S. Patent Application Document		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
Initials*	No.1	Serial Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

				FOI	REIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1	Fore Office ³	ign Patent Do Number ⁴	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	T®
								١.

ı		11-13-2	NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		1	BALZARINI et al. *Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection* Journal Acquired Immune Deficiency Syndromes and Human Retrovirology (1998) 17:296-302	
1	1	2	BALZARINI et al., "Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds", Anticancer Research, vol. 6, 1986, pp. 1077-1084, Belgium, 1986.	
	M	3	BALZARINI et al. "Anti-HIV and anti-HBV activity and resistance profile of 2',3' –dideoxy-3' –thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109" Biochemical and Biophysical Research Communication (1996) 225:363-369	
A				

Examiner Date				
Signature L. E. Crane Considered 03/31/2007	Signature	(b) le are	Considered	03/31/2007

*EXAMINER: Initial if reference cor. sidered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comprunication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_44345.1